Neuronanomedicine: An Up-to-Date Overview

Teleanu, Daniel Mihai; Chircov, Cristina; Grumezescu, Valentina; Teleanu, Raluca Ioana

doi:10.3390/pharmaceutics11030101

Cited by 61 publications

(57 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The progress in pharmaceutical nanotechnology has led to a new class of products, the so-called nanopharmaceuticals [20,21], defined as pharmaceutical drug molecules formulated in nanomaterials. Different types of nanoformulations are being exploited for the treatment of neurodegenerative diseases, cancer, infectious diseases, and others [22][23][24][25][26]. Besides, nanomaterials are also succeeding in offering new advanced tools for imaging and diagnosis [27] which, combined with therapy, have been proposed as nanotheranostics.…”

Section: Characteristics Of Nanoparticles and General Classificationmentioning

confidence: 99%

An Updated Overview on Nanonutraceuticals: Focus on Nanoprebiotics and Nanoprobiotics

Durazzo

Nazhand

Lucarini

et al. 2020

IJMS

View full text Add to dashboard Cite

Over the last few years, the application of nanotechnology to nutraceuticals has been rapidly growing due to its ability to enhance the bioavailability of the loaded active ingredients, resulting in improved therapeutic/nutraceutical outcomes. The focus of this work is nanoprebiotics and nanoprobiotics, terms which stand for the loading of a set of compounds (e.g., prebiotics, probiotics, and synbiotics) in nanoparticles that work as absorption enhancers in the gastrointestinal tract. In this manuscript, the main features of prebiotics and probiotics are highlighted, together with the discussion of emerging applications of nanotechnologies in their formulation. Current research strategies are also discussed, in particular the promising use of nanofibers for the delivery of probiotics. Synbiotic-based nanoparticles represent an innovative trend within this area of interest. As only few experimental studies on nanoprebiotics and nanoprobiotics are available in the scientific literature, research on this prominent field is needed, covering effectiveness, bioavailability, and safety aspects.

show abstract

Section: Characteristics Of Nanoparticles and General Classificationmentioning

confidence: 99%

An Updated Overview on Nanonutraceuticals: Focus on Nanoprebiotics and Nanoprobiotics

Durazzo

Nazhand

Lucarini

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Nanoparticles can be used to entrap or encapsulate chemotherapeutics drugs aiming to improve their BBB permeability and specifically target the BBB or brain tumors through specific ligands. These nanocarriers can present diverse chemistries, including the material and surface functionalization strategies; the characteristics, studies, advantages, and limitations of nanocarriers are extensively reviewed in this special issue by Teleanu et al [427]. For instance, diverse reports use polymeric nanoparticles, solid lipid nanoparticles, liposomes, dendrimers, micelles, inorganic nanoparticles, carbon nanotubes, and quantum dots.…”

Section: Nanoparticles and Targeting Nanocarriersmentioning

confidence: 99%

“…For instance, diverse reports use polymeric nanoparticles, solid lipid nanoparticles, liposomes, dendrimers, micelles, inorganic nanoparticles, carbon nanotubes, and quantum dots. Depending on this chemistry and their functionalization, they may pass through the BBB by diverse pathways, mainly: paracellular, transcellular, or carrier-mediated transport; and receptor-mediated or adsorptive transcytosis [427]. They can be functionalized, for instance, with ligands to cross the BBB via receptor-mediated transcytosis (such as glutathione) or more specific ligands to target tumor cells, such as PEG and glioma homing peptides [428], as well as sialic acid, glucosamine, and concanavalin A, which have shown higher brain accumulation of paclitaxel in rats [429].…”

Section: Nanoparticles and Targeting Nanocarriersmentioning

confidence: 99%

ABC Transporters at the Blood–Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas

et al. 2019

View full text Add to dashboard Cite

Drug delivery into the brain is regulated by the blood–brain interfaces. The blood–brain barrier (BBB), the blood–cerebrospinal fluid barrier (BCSFB), and the blood–arachnoid barrier (BAB) regulate the exchange of substances between the blood and brain parenchyma. These selective barriers present a high impermeability to most substances, with the selective transport of nutrients and transporters preventing the entry and accumulation of possibly toxic molecules, comprising many therapeutic drugs. Transporters of the ATP-binding cassette (ABC) superfamily have an important role in drug delivery, because they extrude a broad molecular diversity of xenobiotics, including several anticancer drugs, preventing their entry into the brain. Gliomas are the most common primary tumors diagnosed in adults, which are often characterized by a poor prognosis, notably in the case of high-grade gliomas. Therapeutic treatments frequently fail due to the difficulty of delivering drugs through the brain barriers, adding to diverse mechanisms developed by the cancer, including the overexpression or expression de novo of ABC transporters in tumoral cells and/or in the endothelial cells forming the blood–brain tumor barrier (BBTB). Many models have been developed to study the phenotype, molecular characteristics, and function of the blood–brain interfaces as well as to evaluate drug permeability into the brain. These include in vitro, in vivo, and in silico models, which together can help us to better understand their implication in drug resistance and to develop new therapeutics or delivery strategies to improve the treatment of pathologies of the central nervous system (CNS). In this review, we present the principal characteristics of the blood–brain interfaces; then, we focus on the ABC transporters present on them and their implication in drug delivery; next, we present some of the most important models used for the study of drug transport; finally, we summarize the implication of ABC transporters in glioma and the BBTB in drug resistance and the strategies to improve the delivery of CNS anticancer drugs.

show abstract

“…This may trigger a stream in βamyloid formation [12]. The role of oxidative stress and damage in various neurodegenerative diseases has led to a focus on the inhibition of these processes as a target with small molecules [13][14]. Some iridoids isolated from different plants have been reported for their potent antioxidant activities [15][16].…”

Section: Introductionmentioning

confidence: 99%

In vitro and in silico approach to determine neuroprotective properties of iridoid glycosides from aerial parts of Scrophularia amplexicaulis by investigating their cholinesterase inhibition and anti-oxidant activities

2020

Biointerface Res Appl Chem

View full text Add to dashboard Cite

Three iridoid glycosides included 6-O-methyl, 1-glucopyranosyl catalpol (Compound 1), 6-O-α-L (3"-O- trans, 4"-O- trans cinnamoyl)-rhamnopyranosyl catalpol (Compound 2) and scropolioside D (Compound 3) were isolated from aerial parts of S. amplexicaulis using chromatographic methods. The structures were determined by different spectroscopic data. The inhibitory effects (IC50 values) of the compounds on cholinesterase (AChE and BChE) was determined by in-vitro assays. Docking studied were performed to investigate receptor-ligands interactions. The antioxidant capacity was evaluated by 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging, 2, 2'-azino-bis[3-ethylbenzothiazoline]-6-sulphonic acid (ABTS) radical cation, cupric ion reducing activity (CUPRAC), ferric reducing antioxidant power (FRAP), phosphomolybdenum and metal chelating assays. AChE and BChE were moderately inhibited by all of the investigated iridoid glycosides (compared to galantamine). Compound 2 and compound 3 showed comparable anti-oxidant effects with the Trolox as the control in phosphomolybdenum assay. Also, compound 1, showed acceptable activities in ABTS radical scavenging and Phosphomolybdenum assays compared to the control.

show abstract

Neuronanomedicine: An Up-to-Date Overview

Cited by 61 publications

References 127 publications

An Updated Overview on Nanonutraceuticals: Focus on Nanoprebiotics and Nanoprobiotics

An Updated Overview on Nanonutraceuticals: Focus on Nanoprebiotics and Nanoprobiotics

ABC Transporters at the Blood–Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas

In vitro and in silico approach to determine neuroprotective properties of iridoid glycosides from aerial parts of Scrophularia amplexicaulis by investigating their cholinesterase inhibition and anti-oxidant activities

Contact Info

Product

Resources

About